In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can cause cancer of the thyroid. Six months ago, the Pharmacovigilance Risk ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

A new study found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond ...